Cochrane Library

Cochrane Database of Systematic Reviews

Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis (Review)

Price M, Günther A, Kwan JSK

Price M, Günther A, Kwan JSK.
Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis.
Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD005501.
DOI: 10.1002/14651858.CD005501.pub3.

www.cochranelibrary.com

WILEY

TABLE OF CONTENTS

[Intervention Review]

Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis

Michelle Price[1], Albrecht Günther[2], Joseph SK Kwan[3]

[1]Royal Bournemouth Hospital, Bournemouth, UK. [2]Department of Neurology, Jena University Hospital, Jena, Germany. [3]Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China

Contact address: Joseph SK Kwan, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pok Fu Lam Road, Hong Kong, China. jskkwan@hku.hk.

Editorial group: Cochrane Epilepsy Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 8, 2014.
Review content assessed as up-to-date: 12 August 2013.

Citation: Price M, Günther A, Kwan JSK. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. *Cochrane Database of Systematic Reviews* 2014, Issue 8. Art. No.: CD005501. DOI: 10.1002/14651858.CD005501.pub3.

ABSTRACT

Background

Intracranial venous thrombosis (ICVT) commonly presents with seizures in the acute period, and some people may develop recurrent seizures in the long term. The prophylactic use of antiepileptic drugs (AEDs) for the management of post-ICVT seizures is controversial, and there is currently no consensus on the optimal management of post-ICVT seizures. This is an updated version of the original Cochrane review published in *The Cochrane Library* 2006, Issue 3.

Objectives

To assess the effects of AEDs for the primary and secondary prevention of seizures related to ICVT.

(1) For the question of primary prevention, we aimed to examine whether AEDs reduce the likelihood of seizures in people who have had an ICVT but have not had a seizure.

(2) For the question of secondary prevention, we aimed to examine whether AEDs reduce the likelihood of further seizures in people who have had an ICVT and at least one seizure.

Search methods

We aimed to identify relevant studies in the Cochrane Epilepsy Group and Cochrane Stroke Group Specialised Registers. We also undertook specialised searches of the Cochrane Central Register of Controlled Trials (CENTRAL, *The Cochrane Library* 2013, Issue 7) and MEDLINE (Ovid 1946 to 22 August 2013) and checked the reference lists of articles retrieved from the searches.

Selection criteria

We considered all randomised and quasi-randomised controlled trials in which participants were assigned to a treatment group (that is, receiving at least one AED) or control group (receiving placebo or no drug).

Data collection and analysis

Both review authors independently screened and assessed the methodological quality of the studies. If studies had been included in the review, then one review author would have extracted the data and the other would have checked the extracted data.

Main results

No relevant studies were found.

Authors' conclusions

There is no evidence to support or refute the use of antiepileptic drugs for the primary or secondary prevention of seizures related to intracranial venous thrombosis. Well-designed randomised controlled trials are urgently needed to inform practice. Since the last version of this review no new studies have been found.

PLAIN LANGUAGE SUMMARY

Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis (ICVT)

Review question

We reviewed the evidence around the use of antiepileptic medication to prevent seizures after intracranial venous thrombosis.

Background

Intracranial venous thrombosis is caused by blood clots in a vein or venous sinus in the brain. This can result in seizure activity. It remains unclear which people with intracranial venous thrombosis should receive antiepileptics as a preventative treatment. We wanted to clarify the potential benefit balanced with the potential side effects from using antiepileptic medication in this group of people.

Study characteristics

No study up to August 2013 met the inclusion criteria for review.

Key results

There is currently no evidence from randomised controlled trials to support or refute the use of antiepileptic drugs for the prevention of seizures related to intracranial venous thrombosis.

BACKGROUND

Description of the condition

This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 3, 2006) on 'Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis'.

Intracranial venous thrombosis (ICVT) is the obstruction of one or more of the cerebral veins or venous sinuses, which causes a rise of venous pressure in its drainage territory (that is, venous hypertension) leading to venous engorgement and brain oedema (Arquizan 2002). This can lead to reduced blood flow in the region. The affected cerebral cortex and underlying white matter may become congested, swollen and haemorrhagic, leading to venous infarction (Arquizan 2002).

ICVT was first described by Ribes in 1825. At that time the condition was largely regarded as fatal, with the majority of diagnoses being made at post-mortem (Benamer 2000). More recently, the diagnosis of ICVT has become easier to confirm with new and less invasive neuroimaging techniques such as magnetic resonance imaging (MRI) (Connor 2002). This has resulted in early treatment and thus much better prognosis than was previously thought possible. In the recent International Study on Cerebral Vein and Dural Sinus Thrombosis, the 30-day case fatality rate was only 3.4%, and the median time from onset to death was 13 days (Canhao 2005a). Another prospective study found that at six months after ICVT 16% of participants had died, 7% were dependent for daily activities, and 77% were independent (Stolz 2005). Treatments of ICVT with anticoagulation, thrombolysis, and corticosteroids have been subjects of several recent Cochrane reviews (Canhao 2002; Ciccone 2004; Stam 2004).

The exact frequency of ICVT in the general population is unclear

(Arquizan 2002). Nevertheless, it is relatively rare and accounts for less than 1% of all strokes (Masuhr 2004). ICVT can occur in all age groups, with the highest incidence being amongst neonates and adults in their third decade. ICVT is more common amongst females (female/male ratio of 1.5 to 5). Due to the wide spectrum of clinical symptoms and gradual onset of symptoms, the diagnosis is often missed or delayed. Important causes and predisposing factors include intracranial or systemic infections, coagulation disorders (for example protein C or S deficiency), vascular trauma (for example neurosurgery, head injury), space-occupying lesions (for example intracranial and extracranial malignancies), hormonal factors (for example the oral contraceptive pill, pregnancy, puerperium), vasculitis (for example lupus erythematosus, Behçet's disease), metabolic disorders (for example homocystinuria, hyperhomocysteinaemia), and others (for example following a lumbar puncture). However, in up to a third of people there may be no identifiable cause (Allroggen 2000; Canhao 2005b; Heller 2003; Masuhr 2004).

There are several key pathophysiological differences between arterial and venous thrombosis in the brain. Firstly, ICVT is widely regarded as a continuing process in which the balance of prothrombotic and thrombolytic processes is disturbed, leading to progression of the venous thrombus with time. This slow growth of the thrombus, together with good collateralisation of venous vessels, could explain why some people present with more gradual onset of symptoms, often over days or weeks. In one retrospective multicentre study of 48 participants 44% presented acutely, 35% presented subacutely, and 21% presented in a chronic state (Terazzi 2005). Secondly, haemorrhagic transformation occurs in a significant proportion of people, probably as a result of raised venous and capillary pressure at and around the site of occlusion (Allroggen 2000).

The clinical presentation of ICVT depends on the extent and site of venous occlusion, the progression of the thrombotic process, and the existence of venous collaterals (Masuhr 2004; Van den Bergh 2005). Occlusion of a large venous sinus may lead to more generalised neurological sequelae, such as intracranial hypertension, epileptic seizures, and altered consciousness, with a poorer outcome. Involvement of isolated cortical veins may present with more focal neurological symptoms such as motor or sensory deficits and focal seizures (Van den Bergh 2005). In some mild cases headache might be the only presenting feature (Cumurciuc 2005).

Description of the intervention

Compared with people with strokes caused by arterial occlusion, those with ICVT are much more likely to experience seizures at the initial presentation and during follow-up (Buccino 2003; De Bruijn 2001; Ferro 2003; Masuhr 2004). In one series of 59 participants with ICVT 47% experienced seizures on admission (De Bruijn 2001). In another series of 142 participants with ICVT 34% experienced seizures within the first two weeks of the event, and 10% experienced seizures after the first two weeks (Ferro 2003). In another series of 77 participants 36% experienced seizures in the acute period (undefined) but only 5% developed recurrent seizures (Preter 1996). The frequency of seizures may be even higher amongst children with ICVT. In a series of 58 children with ICVT 58% experienced seizures on admission, and those presenting with seizures were more likely to have a bad outcome (DeVeber 2001). In Ferro 2003, early seizures were found to be more frequent in people with motor and sensory deficits and in those with computed tomography (CT) or MRI evidence of focal brain oedema, venous infarction, or intracerebral haemorrhage on admission. Furthermore, late seizures were more frequent in people with early seizures and CT or MRI evidence of haemorrhage. However, the relationship between post-ICVT seizures and outcome remains unclear; some studies have identified seizures as a poor prognostic indicator (Benamer 2000; DeVeber 2001; Stolz 2005) whilst others have not found such a relationship (Ferro 2003).

How the intervention might work

The prophylactic use of antiepileptic drugs (AEDs) for the management of post-ICVT seizures is controversial. In Ferro 2003, of the 31 participants who experienced early seizures after ICVT 18 (58%) were prescribed AEDs, and of the 60 participants who did not experience early seizures 12 (20%) were prescribed AEDs. There is currently no consensus on the optimal management of post-ICVT seizures. Whilst some experts recommend prophylactic treatment with AEDs for all people with ICVT because of the high risk of seizures and their potential adverse physiological effects (Einhaupl 1994), others have more recently recommended reserving prophylactic treatment only for those who have already had a seizure, that is, for secondary prevention only (Buccino 2003; Masuhr 2004). On the other hand, Ferro 2003 was specific in recommending that prophylactic treatment should be used in those with proven risk factors for seizures (for example those who have already experienced seizures or who have CT or MRI evidence of haemorrhage).

Why it is important to do this review

This is an update of a previously published review in the Cochrane Database of Systematic Reviews first published in 2006 and previously updated in 2011, which previously found no evidence to support or refute the use of AEDs for the primary or secondary prevention of seizures related to ICVT.

Overall, it remains unclear which people with ICVT should receive prophylactic AEDs and which drug should be used, at what dosage, and for how long (Masuhr 2004). Any potential benefits of using AEDs should also be balanced with their potential side effects.

This systematic review aimed to review updated evidence to assess the potential benefits and risks of AEDs for the prevention of seizures related to ICVT.

OBJECTIVES

To assess the effects of AEDs for the primary and secondary prevention of seizures related to ICVT.

(1) For the question of primary prevention, we aimed to examine whether AEDs reduce the likelihood of seizures in people who have had an ICVT but have not had a seizure.

(2) For the question of secondary prevention, we aimed to examine whether AEDs reduce the likelihood of further seizures in people who have had an ICVT and at least one seizure.

METHODS

Criteria for considering studies for this review

Types of studies

We considered all randomised and quasi-randomised controlled trials in which participants were assigned to a treatment group (that is, receiving at least one AED) or control group (that is, receiving placebo or no drug).

Types of participants

We considered all studies that had recruited participants with a diagnosis of ICVT (including cerebral venous thrombosis and dural sinus thrombosis), regardless of aetiology or method of diagnosis, and who had, or had not, experienced seizures post-ICVT. For studies which reported the results for a mixture of participant groups (for example arterial and venous thromboses) we attempted to separate them and identify those results which were relevant to the participant groups of interest. If this was not possible, despite contacting the investigators, the studies were subjected to a sensitivity analysis to determine the effects of including and excluding the studies. Children or adults with generalised or focal seizures, or both, were included.

Types of interventions

AEDs were any of those listed in the Cochrane Epilepsy Group information page, including carbamazepine, clobazam, clonazepam, diazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, phenobarbitone, primidone, sodium valproate, tiagabine, topiramate, vigabatrin, and zonisamide. We considered all trials in which the intervention was compared with a placebo or with no drug.

Types of outcome measures

Primary outcome measures

The primary outcome was the proportion of participants who experienced clinical seizures in the scheduled follow-up period. In cases where seizures had occurred, their nature (generalised or focal), timing (early or late), and whether an electroencephalography had been performed were noted. The investigators were contacted if the outcome data were not readily available in the published report. As described in the Background, seizures occurring within the first week of ICVT were defined as early seizures, and those occurring after the first week were defined as late seizures (ILAE 1981). Occurrence of recurrent late seizures was defined as post-ICVT epilepsy.

Secondary outcome measures

(1) Proportion of participants who achieved remission for a predefined period of time (for example 12 or 24 months).
(2) Proportion of participants who suffered status epilepticus.
(3) Proportion of participants who withdrew from the allocated treatment within the scheduled follow-up period. This was a composite outcome which takes into account several factors including adverse events, compliance, and effectiveness of treatment. We were particularly interested in the occurrence of side effects for the different AEDs, which may be physical or neurobehavioural (for example problems with memory, attention, and performance skills).
(4) Proportion of participants who were dead or dependent at the end of the scheduled follow-up period. 'Independent' individuals were to be defined as those who did not require regular physical assistance from another person for activities of daily living, such as mobility, dressing, transfers, and feeding. 'Dependent' individuals were to be those who failed to meet one or more of these criteria.

Other outcomes of interest

(1) Quality of life (for example using recognised scoring system such as SF36 and EuroQol).
(2) Duration of hospital stay for the acute phase of recovery after ICVT.
(3) 'Optimal' duration of treatment (that is, length of time that the intervention should be continued).

Search methods for identification of studies

This search was run for the original review in October 2005, and subsequent searches have been run in January 2010, August 2011, and August 2013. For the latest update the following databases were searched:

1. Cochrane Epilepsy Group Specialised Register on 27 August 2013, using the search strategy outlined in Appendix 1.
2. Cochrane Sroke Group Specialised Register on 12 August 2013, using the search strategy outlined in Appendix 2.
3. Cochrane Central Register of Controlled Trials (CENTRAL, *The Cochrane Library* 2013, Issue 7), using the search strategy outlined in Appendix 3.
4. MEDLINE (Ovid 1946 to 22 August 2013). The MEDLINE search strategy is outlined in Appendix 4.

We also checked the reference lists of articles retrieved from the above searches. Where clarification of information was needed, we attempted to contact the investigators of the relevant studies.

Data collection and analysis

Selection of trials

Both review authors screened all the titles, abstracts, and keywords of publications identified by the searches to assess their eligibility. Publications that clearly did not meet the inclusion criteria were excluded at this stage. We obtained a paper copy of the full publication of every study that might possibly be relevant. Both review authors assessed each one according to pre-specified selection criteria. Any disagreement was resolved by discussion.

Assessment of methodological quality

If studies had been included, both review authors would have independently assessed the methodological quality of the included studies and recorded the findings. We would have noted the important aspects of methodology: study design, type of control, method of allocation concealment, completeness of follow-up, and the presence of blinding for assessments of non-fatal outcomes.

Data extraction

If studies had been included, one review author (JK) would have extracted the data onto a data extraction form and the other review author (AG) would have independently checked the extracted data. Data reported by the published sources would have been used for the analyses in this review. Where additional outcome data had been needed, we would have attempted to contact the investigators of the studies. Apart from the methodology and outcome data, we also planned to extract demographic data (for example total number of participants randomised, number of participants per group, age and sex distribution) and possible confounding factors. These could have included certainty of diagnosis of ICVT, location and aetiology of venous thrombosis, severity of condition, presence of a venous infarct, previous history of epilepsy, other co-morbid disorders, method and duration of treatments such as anticoagulation, number of participants who withdrew from the study or were lost during follow-up, and duration of follow-up. Any disagreement would have been resolved by discussion and a consensus decision made.

Data analysis

If studies had been included, data analysis would have abided by the guidelines set out by The Cochrane Collaboration regarding statistical methods. Primary analysis would have been by intention-to-treat. For dichotomous data, we planned to express relative treatment effects as odds or risk ratios, as appropriate, with 95% confidence intervals. For continuous data, we planned to use weighted mean differences with 95% confidence intervals. A P value of less than 0.05 would have been taken as statistically significant. Clinical heterogeneity would have been assessed by the distribution of demographic and prognostic variables across the treatment and control groups. Statistical heterogeneity between studies would have been assessed using the I^2 statistic and the Q test for heterogeneity. Where there was no significant clinical or statistical heterogeneity, and if it appeared sensible to combine the results, we planned to undertake a meta-analysis using a random-effects model.

RESULTS

Description of studies

Results of the search

No study met the inclusion criteria that were set out in this review. For this update, literature searches identified four articles. For the 2011 update, 17 articles were identified. None of the articles identified were of studies that assessed the effects of AEDs for the primary or secondary prevention of seizures related to ICVT. Hence, no data were available for extraction or analysis.

Included studies

No studies met the inclusion criteria.

Excluded studies

All studies identified were excluded as they did not meet the criteria for review.

Risk of bias in included studies

No relevant studies were found.

Effects of interventions

No data from relevant studies were available for analysis.

DISCUSSION

Summary of main results

We did not find any studies that assessed the effects of AEDs for the primary or secondary prevention of seizures related to ICVT. Despite the relatively low incidence of ICVT, the clinical problem of post-ICVT seizures is still an important one. Previous observational studies have reported a high frequency of seizures following ICVT as well as a possible correlation with poor functional outcome. There is currently no consensus on the optimal strategy to prevent post-ICVT seizures, and this systematic review has not found any evidence to support or refute the use of AEDs for this purpose. The balance between the relative benefits and risks of treatment with AEDs remains unclear.

Overall completeness and applicability of evidence

We did not find any studies that assessed the effects of AEDs for the primary or secondary prevention of seizures related to ICVT.

Quality of the evidence

Well-designed randomised controlled trials are needed to provide the necessary high-level evidence to effectively inform clinical practice.

AUTHORS' CONCLUSIONS

Implications for practice

There is no evidence to support or refute the use of antiepileptic drugs for the primary or secondary prevention of seizures related to intracranial venous thrombosis .

Implications for research

No study has been conducted to evaluate the safety and effects of antiepileptic drugs for the primary or secondary prevention of seizures related to intracranial venous thrombosis. Well-designed randomised controlled trials are, therefore, urgently needed to inform clinical practice. Such clinical trials should consider including the following clinically relevant outcomes as outlined in this systematic review.

- Proportion of participants who experience seizures (and status epilepticus) in the scheduled follow-up period.
- Proportion of participants who achieve remission for a predefined period of time.
- Proportion of participants who withdraw from the allocated treatment in the scheduled follow-up period, and the reasons for withdrawal.
- Proportion of participants who are dead or dependent at the end of the scheduled follow-up period.
- Quality of life.
- Duration of hospital stay.
- Optimal duration of treatment.

ACKNOWLEDGEMENTS

We are grateful to the Cochrane Epilepsy Group, Cochrane Stroke Group, the editors, our editorial mentor (Dr Sridharan Ramaratnam) and other peer reviewers for their comments and advice in writing this review.

REFERENCES

Additional references

Allroggen 2000
Allroggen H, Abbot RJ. Cerebral venous sinus thrombosis. *Postgraduate Medical Journal* 2000;**76**(891):12–5.

Arquizan 2002
Arquizan C, Meder JF, Mas JL. Brain venous thrombosis syndromes. In: Bogousslavsky J, Caplan LR editor(s). *Stroke syndromes*. Second Edition. Cambridge: Cambridge University Press, 2002:626–50.

Benamer 2000
Benamer HTS, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolytic therapy?. *Journal of Neurology, Neurosurgery, and Psychiatry* 2000;**69**(4):427–30.

Buccino 2003
Buccino G, Scoditti U, Patteri I, Bertolino C, Mancia D. Neurological and cognitive long-term outcome in patients with cerebral venous sinus thrombosis. *Acta Neurologica Scandinavica* 2003;**107**(5):330–5.

Canhao 2002
Canhão P, Ferro J, Massaro A, Camargo E. Corticosteroids for cerebral vein and dural sinus thrombosis. *Cochrane Database of Systematic Reviews* 2002, Issue 3.

Canhao 2005a
Canhão P, Ferro JM, Lindgren AG, Bousser MG, Stam J, Barinagarrementeria F (ISCVT Investigators). Causes and predictors of death in cerebral venous thrombosis. *Stroke* 2005;**36**(8):1720–5.

Canhao 2005b
Canhão P, Batista P, Falcao F. Lumbar puncture and dural sinus thrombosis - a causal or casual association?. *Cerebrovascular Disease* 2005;**19**(1):53–6.

Ciccone 2004
Ciccone A, Canhão P, Falcao F, Ferro JM, Sterzi R. Thrombolysis for cerebral vein and dural sinus thrombosis. *Cochrane Database of Systematic Reviews* 2004, Issue 1. [DOI: 10.1002/14651858.CD003693.pub2]

Connor 2002
Connor SEJ, Jarosz JM. Magnetic resonance imaging of cerebral venous sinus thrombosis. *Clinical Radiology* 2002; **57**(6):449–61.

Cumurciuc 2005
Cumurciuc R, Crassard I, Sarov M, Valade D, Bousser MG. Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases. *Journal of Neurology, Neurosurgery, and Psychiatry* 2005;**76**(8):1084–7.

De Bruijn 2001
De Bruijn SF, De Hann RJ, Stam J. Clinical features and prognostic factors of cerebral venous thrombosis in a prospective series of 59 patients. *Journal of Neurology, Neurosurgery, and Psychiatry* 2001;**70**(1):105–8.

DeVeber 2001
DeVeber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley DJ, et al. Cerebral venous thrombosis in children. *New England Journal of Medicine* 2001;**345**(6):417–23.

Einhaupl 1994
Einhaupl KM, Masuhr F. Cerebral venous and sinus thrombosis: an update. *European Journal of Neurology* 1994; **1**(2):109–26.

Ferro 2003
Ferro JM, Correia M, Rosas MJ, Pinto AN, Neves G. Seizures in cerebral vein and dural sinus thrombosis. *Cerebrovascular Disease* 2003;**15**(1-2):78–83.

Heller 2003
Heller C, Heinecke A, Junker R, Knofler R, Kosch A, Kurnik K, et al. Cerebral venous thrombosis in children: a multifactorial origin. *Circulation* 2003;**108**(11):1362–7.

Higgins 2005
Higgins JPT, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions* 4.2.4 [updated March 2005]. The Cochrane Collaboration, 2005. Available from www.cochrane-handbook.org.

ILAE 1981
International League Against Epilepsy. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. *Epilepsia* 1981;**22**(4):489–501.

Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Masuhr 2004
Masuhr F, Mehraein S, Einhaupl K. Cerebral venous and sinus thrombosis. *Journal of Neurology* 2004;**251**(1):11–23.

Preter 1996
Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. *Stroke* 1996;**27**(2):243–6.

Stam 2004
Stam J, De Bruijn SFTM, DeVeber G. Anticoagulation for cerebral sinus thrombosis. *Cochrane Database of Systematic Reviews* 2002, Issue 4. [DOI: 10.1002/14651858.CD002005]

Stolz 2005
Stolz E, Rahimi A, Gerriets T, Kraus J, Kaps M. Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and long-term outcome. *Clinical Neurology and Neurosurgery* 2005;**107**(2):99–107.

Terazzi 2005
Terazzi R, Mittino D, Ruda R, Cerrato P, Monaco F, Sciolla R, et al. Cerebral venous thrombosis: a retrospective

multicentre study of 48 patients. *Neurological Science* 2005; **25**(6):311–5.

Van den Bergh 2005

Van den Bergh WM, Van der Schaaf I, Van Gijn J. The spectrum of presentations of venous infarction caused by deep cerebral vein thrombosis. *Neurology* 2005;**65**(2): 192–6.

References to other published versions of this review

Cochrane 2011

Kwan J, Günther A. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. *Cochrane Database of Systematic Reviews* 2011, Issue 12. [DOI: 10.1002/14651858.CD005501.pub2]

* *Indicates the major publication for the study*

DATA AND ANALYSES

This review has no analyses.

APPENDICES

Appendix 1. Cochrane Epilepsy Group Specialised Register search strategy

#1 MeSH DESCRIPTOR Anticonvulsants Explode All WITH AD AE AG AN AI BL CF CS CH CL CT DU EC HI IM IP ME PK PD PO RE ST SD TU TO UR
#2 anticonvulsant* OR antiepilep* OR phenytoin OR valpro* OR carbamazepine OR ethosuximide OR phenobarbit* OR primidone
#3 MeSH DESCRIPTOR Phenobarbital Explode All WITH AD AE AG AA AN AI BL CF CS CH CL CT DU EC HI IM IP ME PK PD PO RE ST SD TU TO UR
#4 clobazam or clonazepam or diazepam or gabapentin or lamotrigine or levetiracetam or lorazapam or oxcarbazepine OR tiagabine or topiramate or vigabatrin or zonisamide
#5 #1 OR #2 OR #3 OR #4
#6 MeSH DESCRIPTOR Intracranial Embolism and Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#7 MeSH DESCRIPTOR Intracranial Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#8 MeSH DESCRIPTOR Sinus Thrombosis, Intracranial Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#9 MeSH DESCRIPTOR Intracranial Embolism Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#10 MeSH DESCRIPTOR Cerebral Veins Explode All WITH AB AH CH CY DE EM EN GD IM IN IR ME MI PS PA PH PP RE RA RI SE SU TR US UL VI
#11 MeSH DESCRIPTOR Cavernous Sinus Explode All WITH AB AH CH CY DE EM EN GD IM IN IR ME MI PS PA PH PP RE RA RI SE SU US UL VI
#12 MeSH DESCRIPTOR Cranial Sinuses Explode All WITH AB AH CH CY DE EM EN GD IM IN IR ME MI PS PA PH PP RE RA RI SE SU US UL VI
#13 MeSH DESCRIPTOR Dura Mater Explode All WITH AB AH BS CH CY DE EM EN GD IM IN ME MI PS PA PH PP RE RA RI SE SU TR US UL VI
#14 #10 OR #11 OR #12 OR #13
#15 MeSH DESCRIPTOR Venous Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#16 MeSH DESCRIPTOR Thrombosis Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#17 MeSH DESCRIPTOR Thromboembolism Explode All WITH BL CF CI CL CO CN DI DH DT EC EM EN EP EH ET GE HI IM ME MI MO NU PS PA PP PC PX RA RI RT RH SU TH US UR VE VI
#18 #15 OR #16 OR #17
#19 #14 AND #18
#20 (sinus* or sinovenous or cerebral venous or cerebral vein*) NEAR5 thrombo*
#21 (cavernous or sagittal venous or sagittal vein* or sinus) NEAR5 thrombo*
#22 cvdst or dct
#23 #6 OR #7 OR #8 OR #9 OR #19 OR #20 OR #21 OR #22
#24 #5 AND #23

Appendix 2. Cochrane Stroke Group Specialised Register search strategy

Search method: 1
Stage: Not specified
Disease: Not specified
Condition: Seizures
Intervention type: Pharmacology
Intervention code: Not specified

Appendix 3. CENTRAL search strategy

#1 (epilep* or seizure* or convulsion*):ti,ab,kw
#2 (anticonvulsant* or antiepilep*):ti,ab,kw
#3 MeSH descriptor Epilepsy explode all trees
#4 MeSH descriptor Seizures explode all trees
#5 MeSH descriptor Anticonvulsants explode all trees
#6 (phenytoin or valpro* or carbamazepine):ti,ab,kw
#7 (ethosuximide OR phenobarbit* or primidone):ti,ab,kw
#8 MeSH descriptor Phenobarbital explode all trees
#9 (clobazam OR clonazepam or diazepam):ti,ab,kw
#10 (gabapentin or lamotrigine or levetiracetam):ti,ab,kw
#11 (lorazapam OR oxcarbazepine OR tiagabine):ti,ab,kw
#12 (topiramate OR vigabatrin OR zonisamide):ti,ab,kw
#13 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Intracranial Embolism and Thrombosis explode all trees
#15 MeSH descriptor Intracranial Thrombosis explode all trees
#16 MeSH descriptor Sinus Thrombosis, Intracranial explode all trees
#17 MeSH descriptor Intracranial Embolism explode all trees
#18 MeSH descriptor Cerebral Veins explode all trees
#19 MeSH descriptor Cavernous Sinus explode all trees
#20 MeSH descriptor Cranial Sinuses explode all trees
#21 MeSH descriptor Dura Mater explode all trees
#22 (#18 OR #19 OR #20 OR #21)
#23 MeSH descriptor Venous Thrombosis explode all trees
#24 MeSH descriptor Thrombosis explode all trees
#25 MeSH descriptor Thromboembolism explode all trees
#26 (#23 OR #24 OR #25)
#27 (#22 AND #26)
#28 (sinus* or sinovenous or cerebral venous or cerebral vein*) NEAR/5 thrombo*
#29 (cavernous or sagittal venous or sagittal vein* or sinus) NEAR/5 thrombo*
#30 (cvdst OR dct)
#31 (#14 OR #15 OR #16 OR #17 OR #27 OR #28 OR #29 OR #30)
#32 (#13 AND #31)

Appendix 4. MEDLINE search strategy

The following search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre 2011).

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Epilepsy/
12. exp Seizures/
13. (epilep$ or seizure$ or convuls$).tw.
14. anticonvulsant$.tw.
15. exp ANTICONVULSANTS/
16. antiepilep$.tw.
17. phenytoin.tw.
18. valpro$.tw.
19. carbamazepine.tw.
20. ethosuximide.tw.
21. phenobarbit$.tw.
22. exp PHENOBARBITAL/
23. primidone.tw.
24. or/11-23
25. "Intracranial Embolism and Thrombosis"/
26. Intracranial Thrombosis/
27. exp Sinus Thrombosis, Intracranial/
28. Intracranial Embolism/
29. Cerebral Veins/
30. Cavernous Sinus/
31. Cranial Sinuses/
32. exp Dura Mater/
33. 29 or 30 or 31 or 32
34. Venous Thrombosis/
35. THROMBOSIS/
36. THROMBOEMBOLISM/
37. 34 or 35 or 36
38. 33 and 37
39. ((sinus$ or sinovenous or cerebral venous or cerebral vein$ or cavernous or sagittal venous or sagittal vein$ or sinus) adj5 thrombo$).tw.
40. (cvdst or cvt).tw.
41. 25 or 26 or 27 or 28 or 38 or 39 or 40
42. 10 and 24 and 41

Earlier versions of this review used the following search strategy. We received guidance from the Cochrane Stroke Group for the stroke section (lines 39 to 54) of the search strategy for MEDLINE. The epilepsy and intervention sections of the search strategy (lines 22 to 36) were standard for the Cochrane Epilepsy Group. Lines 1 to 21 are drawn from the Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE as set out in Appendix 5b of the *Cochrane Handbook for Systematic Reviews of Interventions* (version 4.2.4, updated March 2005) (Higgins 2005).

1. randomized controlled trial.pt.

2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. 1 or 2 or 3 or 4 or 5 or 6
8. (animals not humans).sh.
9. 7 not 8
10. clinical trial.pt.
11. Clinical Trial/
12. (clin$ adj trial$).ab,ti.
13. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
14. exp PLACEBOS/
15. placebo$.ab,ti.
16. random$.ab,ti.
17. exp Research Design/
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. (animals not humans).sh.
20. 18 not 19
21. 9 or 20
22. epilep$.tw.
23. exp EPILEPSY/
24. seizure$.tw. [
25. exp SEIZURES/
26. convulsion$.tw.
27. anticonvulsant$.tw.
28. exp ANTICONVULSANTS/
29. antiepilep$.tw.
30. phenytoin.tw.
31. valpro$.tw.
32. carbamazepine.tw.
33. ethosuximide.tw.
34. phenobarbit$.tw. [
35. exp PHENOBARBITAL/
36. primidone.tw.]
37. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. 21 and 37
39. “Intracranial Embolism and Thrombosis”/
40. Intracranial Thrombosis/
41. exp Sinus Thrombosis, Intracranial/
42. Intracranial Embolism/
43. Cerebral Veins/
44. Cavernous Sinus/
45. Cranial Sinuses/
46. exp Dura Mater/
47. 43 or 44 or 45 or 46
48. Venous Thrombosis/
49. THROMBOSIS/
50. THROMBOEMBOLISM/
51. 48 or 49 or 50
52. 47 and 51
53. ((sinus$ or sinovenous or cerebral venous or cerebral vein$ or cavernous or sagittal venous or sagittal vein$ or sinus) adj5 thrombo$).tw.

54. (cvdst or cvt).tw.
55. 39 or 40 or 41 or 42 or 52 or 53 or 54
56. 38 and 55

WHAT'S NEW

Last assessed as up-to-date: 12 August 2013.

Date	Event	Description
12 August 2013	New search has been performed	Searches updated 12th August 2013; no new trials identified.
12 August 2013	New citation required but conclusions have not changed	Conclusions remain the same.

HISTORY

Protocol first published: Issue 4, 2005

Review first published: Issue 3, 2006

Date	Event	Description
31 August 2011	New search has been performed	Searches updated 31st August 2011; no new trials identified.
17 March 2010	Amended	Co-author's contact details updated.
6 January 2010	New search has been performed	Searches updated 6th January 2010; no new trials identified.
16 September 2008	Amended	Converted to new review format.

CONTRIBUTIONS OF AUTHORS

Dr Joseph Kwan and Dr Albrecht Guenther screened the studies and wrote the original text of the review. Dr Michelle Price screened the studies and added any updated text for this review.

DECLARATIONS OF INTEREST

None.

SOURCES OF SUPPORT

Internal sources

- University of Southampton, UK.

External sources

- No sources of support supplied

INDEX TERMS

Medical Subject Headings (MeSH)

Anticonvulsants [*therapeutic use]; Intracranial Thrombosis [*complications]; Seizures [etiology; *prevention & control]; Venous Thrombosis [*complications]

MeSH check words

Humans